Healthcare / Pharmaceutical RetailersSão Paulo
$6.92
-0.03 (-0.43%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 22% · confianza 25%
FCF escenarios
weak_data · normalized FCF $81.9M · quality 78.3/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
55/100
C
Piotroski
4/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$350M
P/E
14.7x
↓EV/EBITDA
3.9x
↓ROE
2.5%
↑Gross Margin
28.6%
↓Debt/Equity
0.55
↑TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
+21.6%
FCF CAGR
+5.2%
FCF margin
2.7%
FCF / Net income
3.22x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $2.67B · net income $22.6M · FCF $72.8M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $2.67B | $2.67B | $2.16B | $1.75B | $1.48B |
| Net Income | $22.6M | $22.6M | $25.9M | $21.4M | $11.4M |
| EBITDA | $210.4M | $210.4M | $181.0M | $159.8M | $139.9M |
| EPS | 0.45 | 0.45 | 0.51 | 0.42 | 0.22 |
| Gross Margin | 28.6% | 28.6% | 30.6% | 31.6% | 32.1% |
| Operating Margin | 3.1% | 3.1% | 2.9% | 2.9% | 2.4% |
| Net Margin | 0.8% | 0.8% | 1.2% | 1.2% | 0.8% |
| Balance Sheet | |||||
| Debt/Equity | 0.55 | 0.55 | 0.46 | 0.33 | 0.33 |
| Current Ratio | 1.06 | 1.06 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $72.8M | $72.8M | $81.9M | $88.0M | $62.5M |
| Returns | |||||
| ROE | 2.5% | 2.5% | 2.9% | 2.5% | 1.3% |
| Valuation | |||||
| P/E | 14.72 | 14.72 | 10.68 | 14.48 | 18.08 |
| EV/EBITDA | 3.87 | 3.87 | 3.49 | 3.43 | 3.08 |
| P/B | 0.38 | 0.38 | 0.31 | 0.36 | 0.24 |
| Growth & Yield | |||||
| Revenue Growth | 23.4% | 23.4% | 23.5% | 17.9% | — |
| EPS Growth | -12.7% | -12.7% | 21.1% | 88.4% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
3Y implied EPS CAGR
11.2%
EPS terminal req.
$0.61
Spread vs growth
-24.0%
5Y implied EPS CAGR
10.7%
EPS terminal req.
$0.74
Spread vs growth
-23.5%
10Y implied EPS CAGR
10.4%
EPS terminal req.
$1.20
Spread vs growth
-23.1%
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
+27.2%
Start / end P/E
10.6x → 15.5x
EPS bridge
0.51 → 0.45
Residual
-5.8%
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.